http://www.zibb.com/all/theme/cq/Novartis Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Mon, 23 Nov 2009 11:53:51 GMTMon, 23 Nov 2009 11:53:51 GMT608831http://www.zibb.com/all/theme/cq/Novartis http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.zibb.com/article/5687696/Novartis+Up+Since+SmarTrend+s+Buy+RecommendationSmarTrend, our proprietary pattern recognition system, called an Uptrend for Novartis (NYSE:NVS) on July 17, 2009 at $42.41. Since then, Novartis has returned 28.9% as of today's recent price of $54.66. Want to profit from these alerts? Go to www.mysmartrend.com now for a FREE two-week trial. Writehttp://www.zibb.com/article/5687696/Novartis+Up+Since+SmarTrend+s+Buy+RecommendationNovartisMon, 23 Nov 2009 11:53:51 GMThttp://www.drugstorenews.com/story.aspx?id=123399&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+DSNRssChannel+%28Drug+Store+News+RSS+channel%29Novartis on Tuesday announced new interim data from ongoing clinical trials demonstrating that a single 7.5µg dose of the company's influenza A(H1N1) 2009 unadjuvanted vaccine, half of the currently-approved U.S. dose, fulfilled immune response criteria associated with protection in adults and thehttp://www.drugstorenews.com/story.aspx?id=123399&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+DSNRssChannel+%28Drug+Store+News+RSS+channel%29NovartisWed, 18 Nov 2009 10:50:00 GMThttp://www.businessweekly.co.uk/2009111835852/life-sciences/horizon-seals-eight-figure-deal-with-novartis.htmlCambridge personalised medicine company Horizon Discovery, which last night scooped both the top UK company and best tech start up prizes in the Government’s new iawards, has followed up in spectacular fashion by announcing an eight-figure deal with pharma giant, Novartis.http://www.businessweekly.co.uk/2009111835852/life-sciences/horizon-seals-eight-figure-deal-with-novartis.htmlNovartisWed, 18 Nov 2009 09:38:09 GMThttp://rdmag.com/News/FeedsAP/2009/11/life-sciences-novartis-lower-dose-of-flu-vaccine-sufficient/Drug maker Novartis says lower dose of swine flu vaccine sufficient to guarantee immunityhttp://rdmag.com/News/FeedsAP/2009/11/life-sciences-novartis-lower-dose-of-flu-vaccine-sufficient/NovartisTue, 17 Nov 2009 12:26:26 GMThttp://www.sfgate.com/cgi-bin/article.cgi?f=/n/a/2009/11/17/financial/f035737S23.DTL&feed=rss.businessPharmaceutical maker Novartis AG said Tuesday a U.S. clinical study suggests that half a dose of its swine flu vaccine may be sufficient to protect people from the virus and could allow many more to be immunized with current supplies. Clinical trials of... <ahttp://www.sfgate.com/cgi-bin/article.cgi?f=/n/a/2009/11/17/financial/f035737S23.DTL&feed=rss.businessNovartisTue, 17 Nov 2009 11:58:43 GMThttp://www.newsvine.com/_news/2009/11/17/3510785-novartis-lower-dose-of-flu-vaccine-sufficientPharmaceutical maker Novartis AG said Tuesday a U.S. clinical study suggests that half a dose of its swine flu vaccine may be sufficient to protect people from the virus and could allow many more to be immunized with current supplies.http://www.newsvine.com/_news/2009/11/17/3510785-novartis-lower-dose-of-flu-vaccine-sufficientNovartisTue, 17 Nov 2009 11:57:37 GMThttp://www.marketwatch.com/story/novartis-smaller-flu-vaccine-doses-suffice-2009-11-17?siteid=yhoof2TEL AVIV (MarketWatch) -- Novartis AG, the Basel health-care giant, on Tuesday reported progress from clinical trials of its influenza A (H1N1) vaccine. In clinical trials, a single dose of the vaccine, which is half the currently approved U.S. dose,http://www.marketwatch.com/story/novartis-smaller-flu-vaccine-doses-suffice-2009-11-17?siteid=yhoof2NovartisTue, 17 Nov 2009 07:15:13 GMThttp://www.foxbusiness.com/story/markets/industries/health-care/novartis-smaller-flu-vaccine-doses-suffice/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+foxbusiness%2Flatest+%28FOXBusiness.com+-+Latest+News%29Novartis: Smaller Flu-vaccine Doses Sufficehttp://www.foxbusiness.com/story/markets/industries/health-care/novartis-smaller-flu-vaccine-doses-suffice/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+foxbusiness%2Flatest+%28FOXBusiness.com+-+Latest+News%29NovartisTue, 17 Nov 2009 07:15:00 GMThttp://uk.reuters.com/article/idUKTRE5AG0Z720091117?feedType=RSS&feedName=healthNewsMolt&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+reuters%2FUKHealth+%28News+%2F+UK+%2F+Health+%26+Drugs%29ZURICH (Reuters) - A U.S. clinical study suggests that just half a dose of the Novartis AG H1N1 vaccine may be enough to generate a protective immune response, the Swiss drugmaker said on Tuesday. Novartishttp://uk.reuters.com/article/idUKTRE5AG0Z720091117?feedType=RSS&feedName=healthNewsMolt&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+reuters%2FUKHealth+%28News+%2F+UK+%2F+Health+%26+Drugs%29NovartisTue, 17 Nov 2009 06:27:34 GMThttp://www.genengnews.com/news/bnitem.aspx?name=68751783Novartis’ recently sanctioned unadjuvanted influenza A (H1N1) 2009 monovalent vaccine may be effective at just half the dose currently stipulated under its FDA approval, accohttp://www.genengnews.com/news/bnitem.aspx?name=68751783NovartisTue, 17 Nov 2009 00:00:00 GMThttp://www.cnbc.com/id/33985469A U.S. clinical study suggests that just half a dose of the Novartis AG H1N1 vaccine may be enough to generate a protective immune response, the Swiss drugmaker said on Tuesday.http://www.cnbc.com/id/33985469NovartisTue, 17 Nov 2009 00:00:00 GMThttp://www.slaw.ca/2009/11/16/this-weeks-biotech-highlights-37/While I bounced back and forth between Toronto and New York this week, a lot of other things were bouncing around in the world of biotech:The U.S. stimulus funding to promote adoption of electronic medical records bounced across the border to Ontario, where a new program was implemented through thehttp://www.slaw.ca/2009/11/16/this-weeks-biotech-highlights-37/NovartisMon, 16 Nov 2009 15:00:04 GMThttp://seekingalpha.com/article/173179-novartis-says-weak-ip-protection-makes-india-r-d-impossible?source=yahooNovartis (NYSE: NVS) once again said that India is not a place to do R&D because its IP laws are not strong enough to protect discoveries. In 2006, Novartis made a commitment to build a $125 million R&D facility in Hyderabad.http://seekingalpha.com/article/173179-novartis-says-weak-ip-protection-makes-india-r-d-impossible?source=yahooNovartisFri, 13 Nov 2009 10:40:05 GMThttp://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=10625• Ahead of World Diabetes Day, Novartis highlights need for patients to become more active partners in managing their type 2 diabetes • Campaign raises awareness of difference between symptoms and treatment side effects, such as hypoglycemia and weihttp://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=10625NovartisFri, 13 Nov 2009 01:00:00 GMThttp://www.newratings.com/en/main/company_headline.m?id=1989635NEW YORK, November 12 (newratings.com) - Analysts at Barclays Capital initiate coverage of Novartis AG (ticker: NVS) with an "underweight" rating. The target price is set to $48. [more]http://www.newratings.com/en/main/company_headline.m?id=1989635NovartisThu, 12 Nov 2009 18:14:37 GMThttp://www.dmnews.com/Novartis-200-million-integrated-campaign-promotes-heartburn-drug/article/157658/On November 12, pharmaceutical company Novartis launched a $200 million integrated ad campaign with agencies Deutsch and Tribal DDB for its new OTC heartburn drug Prevacid 24HR.http://www.dmnews.com/Novartis-200-million-integrated-campaign-promotes-heartburn-drug/article/157658/NovartisThu, 12 Nov 2009 14:47:49 GMThttp://multivu.prnewswire.com/mnr/prevacid/40945/®24HR (lansoprazole delayed-release capsules 15 mg/acid reducer) over-the-counter in pharmacies and retail stores across the US to treat frequent heartburn.http://multivu.prnewswire.com/mnr/prevacid/40945/NovartisThu, 12 Nov 2009 06:45:00 GMThttp://pharmtech.findpharma.com/pharmtech/Manufacturing/Novartis-Updates-Vaccine-Progress-in-Germany-Acqui/ArticleStandard/Article/detail/640743?ref=25Novartis reported that German regulatory authorities approved its adjuvanted cell culture-based Influenza A (H1N1) 2009 monovalent vaccine, Celtura. The company also said it will acquire a stake in Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical.http://pharmtech.findpharma.com/pharmtech/Manufacturing/Novartis-Updates-Vaccine-Progress-in-Germany-Acqui/ArticleStandard/Article/detail/640743?ref=25NovartisThu, 12 Nov 2009 05:00:00 GMThttp://www.biospace.com/news_story.aspx?StoryID=162319&full=1SHENZHEN, China, Nov. 9 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS.PK) www.htdsmedical.com, announced today that Novartis, a US$41 billion international healthcare company, is acquiring an 85% stake in HTDS' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.http://www.biospace.com/news_story.aspx?StoryID=162319&full=1NovartisTue, 10 Nov 2009 12:00:00 GMThttp://www.bloomberg.com/apps/news?pid=20601103&sid=alzuLn2Pwh3IThe [bn:WBTKR=1000L:US] U.S. Supreme Court [] today considers a patent dispute that will determine how much legal protection is afforded abstract business innovations and has drawn in companies including [bn:WBTKR=MSFT:US] Microsoft Corp. [], [bn:WBTKR=GOOG:US] Google Inc. [] and Novartis Corp.http://www.bloomberg.com/apps/news?pid=20601103&sid=alzuLn2Pwh3INovartisMon, 09 Nov 2009 06:07:20 GMThttp://pubs.acs.org/cen/news/87/i45/8745notw5.htmlPharma Strategy. Novartis makes major R&D and vaccines investments in China.http://pubs.acs.org/cen/news/87/i45/8745notw5.htmlNovartisFri, 06 Nov 2009 15:30:00 GMThttp://www.manufacturing.net/News-Novartis-To-Make-Swine-Flu-Vaccine-From-Cells-110509.aspxWith demand high because of the pandemic, companies are trying to find a more efficient way of producing swine flu vaccine than cultivating seed virus in chicken eggs.http://www.manufacturing.net/News-Novartis-To-Make-Swine-Flu-Vaccine-From-Cells-110509.aspxNovartisThu, 05 Nov 2009 14:21:00 GMThttp://www.smartmoney.com/breaking-news/on/?story=ON-20091105-000406-0355&afl=yahooZURICH -(Dow Jones)- Swiss drugmaker Novartis AG (NVS) Thursday said it received regulatory approval to sell its cell-based swine flu vaccine in Germany, marking an important milestone in gaining acceptance for newer rapid ways of producing vaccines.http://www.smartmoney.com/breaking-news/on/?story=ON-20091105-000406-0355&afl=yahooNovartisThu, 05 Nov 2009 07:55:00 GMThttp://www.ameinfo.com/214839.htmlThe UAE's first dedicated Breast Cancer Conference will lead to improvements in the quality of care through the dissemination of best practice, and the strengthening of links between the country's...http://www.ameinfo.com/214839.htmlNovartisWed, 04 Nov 2009 09:50:02 GMThttp://www.ft.com/cms/s/eb75ac34-c8e2-11de-8f9d-00144feabdc0,Authorised=false.html?_i_location=http%3A%2F%2Fwww.ft.com%2Fcms%2Fs%2F0%2Feb75ac34-c8e2-11de-8f9d-00144feabdc0.html%3Fftcamp%3Drss%26nclick_check%3D1&_i_referer=&ftcamp=rss&nclick_check=1The latest drugs, healthcare and pharmaceutical news from the Financial Times, with expert company and industry analysis on FT.comhttp://www.ft.com/cms/s/eb75ac34-c8e2-11de-8f9d-00144feabdc0,Authorised=false.html?_i_location=http%3A%2F%2Fwww.ft.com%2Fcms%2Fs%2F0%2Feb75ac34-c8e2-11de-8f9d-00144feabdc0.html%3Fftcamp%3Drss%26nclick_check%3D1&_i_referer=&ftcamp=rss&nclick_check=1NovartisWed, 04 Nov 2009 02:00:00 GMT